Compounded semaglutide vs brand name Wegovy: what is the real difference?

Short answer

• The real difference is regulation, quality control, and evidence. Wegovy (Novo Nordisk) is an FDA‑approved, factory‑manufactured semaglutide product with a labeled dose and proven safety/efficacy for weight loss. “Compounded semaglutide” is made by a pharmacy from bulk active ingredient under compounding rules — it can be cheaper and accessible, but it’s not FDA‑approved as a finished drug, may vary in purity, potency, sterility, stability, device/dosing, and lacks the same clinical testing and manufacturer support.

Key points explained

1. Regulatory status and clinical evidence

• Wegovy: FDA‑approved for chronic weight management at a defined dose/titration schedule (clinical trials, standard labeling, known adverse‑event profile).
• Compounded semaglutide: not an FDA‑approved finished product. It hasn’t gone through the same large clinical trials or labeling review for weight loss as Wegovy.

1. Manufacturing quality and testing

• Wegovy is made under strict Good Manufacturing Practice (GMP) and lot‑tested by the manufacturer.
• Compounded products depend on the pharmacy’s practices. Some compounding pharmacies are high quality (USP <797>/<800> compliance, PCAB accreditation, or registered 503B outsourcing facilities), but others may use bulk API sources with variable purity, and batch testing may be inconsistent.

1. Sterility and safety for injectables

• Wegovy pens are produced sterile and designed for weekly subcutaneous dosing.
• Compounded injectable vials or syringes carry a nontrivial risk if aseptic technique, sterility testing, endotoxin testing, or storage stability aren’t adequate. Contamination or incorrect concentration can cause harm.

1. Dosing, devices, and labeling

• Wegovy comes in prefilled pens with consistent concentration and clear titration instructions.
• Compounded semaglutide may be supplied in vials, syringes, or pens with different concentrations — raising dosing errors risk. Pens designed specifically for the product are safer and easier to dose.

1. Legal, insurance, and support

• Wegovy has manufacturer support programs and is sometimes (but not always) covered by insurance or eligible for savings programs (Novo Nordisk offers patient support and savings for eligible patients).
• Compounded drugs are often not covered by insurance; there’s little to no manufacturer support. Adverse events from compounded products can be harder to track and report.

1. Cost

• Wegovy is expensive for many. Compounded semaglutide is often cheaper, which is why many people choose it — but the lower cost comes with the quality/safety tradeoffs above.

Other practical distinctions

• Ozempic (also semaglutide, Novo Nordisk) is FDA‑labeled for type 2 diabetes at different doses. People sometimes use Ozempic off‑label for weight loss; Wegovy is the approved weight‑loss formulation and dose.
• Newer approved options for weight management include tirzepatide (Zepbound — Eli Lilly) for patients where appropriate; these are FDA‑approved products with clinical data and should be discussed with your clinician.

If you’re considering a compounded product: what to ask and look for

• Is the pharmacy a 503B outsourcing facility or a 503A compounder? (503B facilities are overseen by the FDA.)
• Is the pharmacy accredited by the Pharmacy Compounding Accreditation Board (PCAB) or compliant with USP <797>?
• Can they provide a Certificate of Analysis (COA) for the batch showing potency and purity and sterility/endotoxin testing?
• What is the source of the API (active pharmaceutical ingredient)? Is it a GMP supplier?
• How is it supplied (vial vs prefilled pen), concentration (mg/mL), expiration/stability, and storage instructions?
• What training/support do they provide for dosing/injection? Is there a return/refund policy for adverse events?
• Avoid buying semaglutide from unverified overseas websites or marketplaces — those are high risk.

Bottom line / recommendation

• If you want the safest, most predictable option with proven efficacy, use the FDA‑approved product Wegovy (Novo Nordisk) or another FDA‑approved weight‑loss drug prescribed by your clinician.
• If Wegovy is unaffordable or unavailable and you’re considering compounded semaglutide, only use it after careful vetting of the compounding pharmacy (preferably a PCAB‑accredited or FDA‑registered 503B facility), get batch COAs and sterility testing, and discuss risks with your prescriber.

If you’d like, I can:

• Help you compare cost‑saving options for Wegovy (manufacturer savings programs, insurance appeal tips, coupons);
• Walk through questions to vet a specific compounding pharmacy if you have its name.